Katherine High

Katherine High was a pioneer in translating gene therapy from laboratory concept to clinical reality, leading the first successful AAV gene therapy trials for hemophilia B that demonstrated sustained therapeutic protein expression from a single vector administration. Her clinical translation expertise has been applied to cancer gene therapy programs, particularly in manufacturing scalable AAV and lentiviral vectors meeting clinical-grade standards. She has navigated regulatory pathways for gene therapy approval and established safety monitoring frameworks applicable to cancer gene therapy. Her experience bridging gene therapy from rare disease to oncology applications has informed the design of cancer gene therapy clinical trials.